NASDAQ:ARNA - Arena Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$49.80 -0.12 (-0.24 %)
(As of 02/19/2019 03:32 PM ET)
Previous Close$49.92
Today's Range$49.40 - $49.92
52-Week Range$30.00 - $50.05
Volume8,394 shs
Average Volume451,818 shs
Market Capitalization$2.46 billion
P/E Ratio-18.97
Dividend YieldN/A
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. Its proprietary investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod that is in Phase II trials for treating immune and inflammatory conditions with primary focus on ulcerative colitis and hepatic conditions, as well as for primary biliary cholangitis and pyoderma gangrenosum; and APD371, which is in Phase II trial for the treatment of pain associated with Crohn's disease. The company has collaboration agreements with Everest Medicines Limited; Axovant Sciences GmbH; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ARNA



Sales & Book Value

Annual Sales$21.34 million
Book Value$5.28 per share


Net Income$-91,400,000.00
Net Margins-452.86%


Market Cap$2.46 billion

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals shares reverse split before market open on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its earnings results on Monday, August, 6th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the Zacks' consensus estimate of ($0.64) by $0.01. The biopharmaceutical company earned $4 million during the quarter, compared to the consensus estimate of $3.91 million. Arena Pharmaceuticals had a negative net margin of 452.86% and a negative return on equity of 23.66%. The firm's revenue for the quarter was up 110.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.77) EPS. View Arena Pharmaceuticals' Earnings History.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 13th 2019. View Earnings Estimates for Arena Pharmaceuticals.

What price target have analysts set for ARNA?

8 Wall Street analysts have issued 12-month price targets for Arena Pharmaceuticals' shares. Their forecasts range from $55.00 to $79.00. On average, they expect Arena Pharmaceuticals' stock price to reach $63.6250 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.

What is the consensus analysts' recommendation for Arena Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, ": After assuming coverage of ARNA, we are publishing our new model, decreasing our 12-mo. price target from $67 to $62, and maintaining an Overweight rating. We updated our model for Arena’s deal with United Therapeutics (NC) for ralinepag. Our base case peak sales are $2.5B for etrasimod, and we also give some credit to Ph2 olorinab in pain and ralenipag royalties. We think bowel disease represents a large and growing market in immunology, and etrasimod is well-positioned with strong efficacy & safety in ulcerative colitis compared to Celgene’s (OW) S1P1 ozanimod." (1/28/2019)
  • 2. According to Zacks Investment Research, "Arena Pharmaceuticals reported is focused on developing its three pipeline candidates – ralinepag, etrasimod and olorinab. The company has signed an agreement with United Therapeutics to divest Ralinepag for $1.2 billion. The company’s collaboration agreements provide milestone payments and steady revenue stream from royalties on Belviq sales. Meanwhile, the company’s decision to sell its manufacturing operations to focus on pipeline is prudent, in our view. However, all of Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in a competitive market. Shares of the company have outperformed the industry in the past six months." (1/15/2019)
  • 3. Needham & Company LLC analysts commented, "Arena mgmt provided a corporate update today in a 4Q17 conference call. Mgmt reiterated guidance for top-line results from etrasimod Phase 2 trial in Ulcerative Colitis (UC) later this month. Preclinical and Phase 1 data suggest the drug has the potential for differentiation in the S1P receptor modulator space. We await outcome, maintaining HOLD. Mgmt also discussed ralinepag Phase 3 trial design in Pulmonary Arterial Hypertension (PAH). Three trials are planned, two of which mgmt believes are independently sufficient for regulatory approval. Mgmt plans to provide more details around cost and time to completion mid-2018 after protocols are finalized." (3/14/2018)

Has Arena Pharmaceuticals been receiving favorable news coverage?

Headlines about ARNA stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:
  • Mr. Kevin R. Lind, CFO & Exec. VP (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Chief Bus. Officer & Exec. VP (Age 51)
  • Dr. Preston S. Klassen, Chief Medical Officer and Exec. VP of R&D (Age 50)
  • Mr. Amit D. Munshi, CEO, Pres & Director (Age 51)

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.67%), Partner Fund Management L.P. (6.10%), Perceptive Advisors LLC (2.89%), Northern Trust Corp (1.21%), Geode Capital Management LLC (1.14%) and Dimensional Fund Advisors LP (1.07%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Preston Klassen and Steven W Spector. View Institutional Ownership Trends for Arena Pharmaceuticals.

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tekla Capital Management LLC, Eversept Partners LP, Barclays PLC, Squarepoint Ops LLC, First Trust Advisors LP, Chartwell Investment Partners LLC and Emerald Advisers LLC. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Preston Klassen and Steven W Spector. View Insider Buying and Selling for Arena Pharmaceuticals.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was acquired by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Dimensional Fund Advisors LP, ETF Managers Group LLC, Candriam Luxembourg S.C.A., Perceptive Advisors LLC, Geode Capital Management LLC, Bank of New York Mellon Corp and Prosight Management LP. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $49.80.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $2.46 billion and generates $21.34 million in revenue each year. The biopharmaceutical company earns $-91,400,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. Arena Pharmaceuticals employs 159 workers across the globe.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]

MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  311 (Vote Outperform)
Underperform Votes:  352 (Vote Underperform)
Total Votes:  663
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by Staff

Featured Article: What are no-load funds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel